clinical development comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-23. Numbers and descriptions here follow the published literature rather than marketing material.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine (deoxyepinephrine or N-methyldopamine), used in ophthalmology. It induces mydriasis. It also has been investigated for use in the treatment of congestive heart failure. It acts on D1 and α-adrenergic receptors as an agonist. Ibopamine was first prepared by Casagrande and co-workers. Instilled at 2% concentration, ibopamine exhibits several functions at ocular level such as pre- and post-operative mydriatic activity, D1 dopaminergic activity, etc.
== Prevention == A study was done to compare the sperm outcomes of individuals with or without infection of the human papilloma virus (HPV), which currently affects 79 million Americans. The study concluded that individuals who had not been infected with HPV had higher rates of sperm motility, functionality, and concentration of sperm. This study suggests that individuals who do not contract HPV or who are vaccinated against HPV have better fertility outcomes than those who are not vaccinated or who have contracted HPV. Vaccination against HPV with Gardasil9 can be administered by hospitals, clinics or most pharmacies in 3 doses ideally at age 11–12 in both girl and boys, but can be taken up to age 45 per Center of Disease Control (CDC) guidelines.
With the new season of the J.League commencing in March 1995, Wenger set about assembling his squad and backroom staff. He hired former Valenciennes manager Boro Primorac, whom he had befriended during the match-fixing scandal, as his assistant. Alexandre Torres joined Nagoya after Wenger identified the defender by watching Brazilian football on the television, and the manager brought in Franck Durix and his former player Passi. Nagoya finished bottom of the J.League the season before Wenger's arrival, and continued their poor form into the following campaign, losing several matches in a row. In response to the situation, Wenger altered his managerial style, becoming less amicable with his players and openly questioning their desire. To boost morale, he took his squad to Versailles for their mid-season break, where they went through a rigorous, but creative, training regime. Players were expected to make decisions for themselves on the pitch, instead of relying on the manager; Wenger was reported to have shouted to his players "Don't look at me to ask me what to do with the ball!" and "Decide for yourself! Why don't you think it out?" One player who greatly benefited from Wenger's guidance was Dragan Stojković, a midfielder whose disciplinary record improved considerably. Wenger's methods had the desired effect – Nagoya won 17 of their following 27 games to finish runners-up in 1995. He shortly received the J. League Manager of the Year award for 1995, while Stojković claimed the player's honour.
The first national team was in the kingdom that existed between the two world wars. The Football Federation of what was then the Kingdom of Serbs, Croats and Slovenes was founded in Zagreb in 1919 under the name Jugoslavenski nogometni savez (and admitted into FIFA), and the national team played its first international game at the Summer Olympics in Antwerp in 1920. The opponent was Czechoslovakia, and the historic starting eleven that represented Kingdom of SCS on its debut were: Dragutin Vrđuka, Vjekoslav Župančić, Jaroslav Šifer, Stanko Tavčar, Slavin Cindrić, Rudolf Rupec, Dragutin Vragović, Artur Dubravčić, Emil Perška, Ivan Granec, and Jovan Ružić. They lost by a huge margin 0–7, but nonetheless got their names in the history books.
CH3OH + H2S → CH3SH + H2O Such reactions are conducted in the presence of acidic catalysts. The other principal route to thiols involves the addition of hydrogen sulfide to alkenes. Such reactions are usually conducted in the presence of an acid catalyst or UV light. Halide displacement, using the suitable organic halide and sodium hydrogen sulfide has also been used. Another method entails the alkylation of sodium hydrosulfide.
Sources: en.wikipedia.org
Diethyl ether could also be mixed with other anesthetic agents such as chloroform to make C.E. mixture, or chloroform and alcohol to make A.C.E. mixture. In the mid-20th century the growing use of electrical cauterization in surgery necessitated a switch to non-flammable anesthesia. In the 21st century, ether is rarely used. The use of flammable ether was displaced by nonflammable fluorinated hydrocarbon anesthetics. Halothane was the first such anesthetic developed and other currently used inhaled anesthetics, such as isoflurane, desflurane, and sevoflurane, are halogenated ethers. Diethyl ether was found to have undesirable side effects, such as post-anesthetic nausea and vomiting. Modern anesthetic agents reduce these side effects.
After tobacco is harvested, it is cured (dried), and then aged to improve its flavor. There are four common methods of curing tobacco: air curing, fire curing, flue curing, and sun curing. The curing method used depends on the type of tobacco and its intended use. Air-cured tobacco is sheltered from wind and sun in a well-ventilated barn, where it air-dries for six to eight weeks. Air-cured tobacco is low in sugar, which gives the tobacco smoke a light, sweet flavour, and high in nicotine. Cigar and burley tobaccos are air-cured. In fire curing, smoke from a low-burning fire on the barn floor permeates the leaves. This gives the leaves a distinctive smoky aroma and flavor. Fire curing takes three-to-ten weeks and produces a tobacco low in sugar and high in nicotine. Pipe tobacco, chewing tobacco, and snuff are fire-cured. Flue-cured tobacco is kept in an enclosed barn heated by flues (pipes) of hot air, but the tobacco is not directly exposed to smoke. This method produces cigarette tobacco that is high in sugar and has medium-to-high levels of nicotine. It is the fastest method of curing, requiring about a week. Virginia tobacco that has been flue-cured is also called bright tobacco, because flue curing turns its leaves gold, orange, or yellow. Sun-cured tobacco dries uncovered in the sun. This method is used in Greece, Turkey, and other Mediterranean countries to produce oriental tobacco. Sun-cured tobacco is low in sugar and nicotine and is used in cigarettes.
Bromazolam (XLI-268) is a triazolobenzodiazepine (TBZD) which was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. It is the bromo instead of chloro analogue of alprazolam and has similar sedative and anxiolytic effects to it and other benzodiazepines. Bromazolam is a non subtype selective agonist at the benzodiazepine site of GABAA receptors, with a binding affinity of 2.81 nM at the α1 subtype, 0.69 nM at α2 and 0.62 nM at α5. The "common" dosage range for users of bromazolam was reported to be 1–2 mg, suggesting its potency is similar to alprazolam.
Soldiers and ninja also used "pills", small ball-shaped medicinal rations consumed in emergencies or long missions, of which there were three types: hyorogan ("ration pills"), made with various flours, sugary substances, and spices to provide quick energy; kikatsugan ("hunger pills"), made with starchy ingredients to provide endurance; and suikitsugan ("thirst pills"), made from umeboshi, bakumondoto, and sugar to encourage saliva production. Tang dynasty soldiers ate primarily millet porridge, but before a deployment, they would have a large and elaborate banquet, with another large meal before a battle. Song dynasty soldiers were issued money for food and bought meat, vegetables, pickles, and salt locally. Grain supply issues meant they relied less on grain rations than in prior generations. During the Ming dynasty, sesame seed cakes, which could last long periods of time, became standard military food and wheat began to take an important position in rations. The imperial government spent significant amounts of money on the military, investing more into supplying the army with food than previous dynasties. A system of military farmlands, comprising 10% of cultivated land, was organized to supply the army. The state assigned 10% to 20% of military households in each region with running military farms and provided them with seeds and tools to grow grain. Other farmers delivered grain to supplement bad growing seasons. In 1392, this system was designed to feed 1.2 million soldiers.
Sources: en.wikipedia.org
Very low voltages are inefficient since the lead wires would conduct too much heat away from the filament, so the practical lower limit for incandescent lamps is 1.5 volts. Very long filaments for high voltages are fragile, and lamp bases become more difficult to insulate, so lamps for illumination are not made with rated voltages over 300 volts. Some infrared heating elements are made for higher voltages, but these use tubular bulbs with widely separated terminals.
=== True protein === In at least one segment of the food industry, the dairy industry, some countries (at least the U.S., Australia, France and Hungary) have adopted "true protein" measurement, as opposed to crude protein measurement, as the standard for payment and testing: "True protein is a measure of only the proteins in milk, whereas crude protein is a measure of all sources of nitrogen and includes nonprotein nitrogen, such as urea, which has no food value to humans. ... Current milk-testing equipment measures peptide bonds, a direct measure of true protein." Measuring peptide bonds in grains has also been put into practice in several countries including Canada, the UK, Australia, Russia and Argentina where near-infrared reflectance (NIR) technology, a type of infrared spectroscopy is used. The more traditional approach to true protein analysis is amino acid analysis. Data from such analysis has additional nutritional meaning, as humans and other animals have specific requirements for essential amino acids. The Food and Agriculture Organization of the United Nations (FAO) recommends that only amino acid analysis be used to determine protein in, inter alia, foods used as the sole source of nourishment, such as infant formula, but also provides: "When data on amino acids analyses are not available, determination of protein based on total N content by Kjeldahl (AOAC, 2000) or similar method ...
Accounts of exactly what happened vary but it seems likely that he was mockingly offering it to the Labour benches, not, as some alleged, "brandishing" it – an illusion caused by Prior pulling his other arm down. Thatcher was furious. Speaker Thomas suspended the sitting and made Heseltine wait until next day to apologise so that tempers could cool. Heseltine was faced with calls for his resignation from the Shadow Cabinet; he thought it would play well with the public, but in Crick's view it helped to cement a reputation for impulsiveness and poor judgement. In autumn 1976 Heseltine was reshuffled, against his will, to the job of Shadow Environment Secretary. He was particularly cross at having to give up the job of Shadow Industry Secretary to John Biffen. He accepted on condition that he would not have to take the Environment job when the Conservatives returned to office. As Benn had given way to Eric Varley there was no longer such a need for aggressive campaigning on Industry, and Thatcher, who had herself been Shadow Environment Secretary in 1974, wanted him to campaign on council house sales (Heseltine offered up to 50% discounts for tenants who bought their homes) and reform of the rates, as she thought his predecessor Timothy Raison ineffective.
== Biochemistry == Antifreeze protein, class of polypeptides produced by certain fish, vertebrates, plants, fungi and bacteria Conjugated protein, protein that functions in interaction with other chemical groups attached by covalent bonds Conformational ensembles, the study of the structure of flexible proteins and their possible configurations, that are represented by sets of models called conformational ensembles or structural ensembles Denatured protein, protein which has lost its functional conformation Matrix protein, structural protein linking the viral envelope with the virus core Intrinsically disordered proteins or intrinsically unstructured proteins or simply flexible proteins are protein that, lacking a fixed tertiary structure, can assume various conformations based on the conditions within which they interact with within the cell Protein A, bacterial surface protein that binds antibodies Protein A/G, recombinant protein that binds antibodies Protein C, anticoagulant Protein G, bacterial surface protein that binds antibodies Protein L, bacterial surface protein that binds antibodies Protein S, plasma glycoprotein Protein Z, glycoprotein Protein catabolism, the breakdown of proteins into amino acids and simple derivative compounds Protein complex, group of two or more associated proteins Protein dynamics, the study of the transitions between protein conformational states Protein electrophoresis, method of analysing a mixture of proteins by means of gel electrophoresis Protein folding, process by which a protein assumes its characteristic functional shape or tertiary structure Protein isoform, version of a protein with some small differences Protein kinase, enzyme that modifies other proteins by chemically adding phosphate groups to them Protein ligands, atoms, molecules, and ions which can bind to specific sites on proteins Protein microarray, piece of glass on which different molecules of protein have been affixed at separate locations in an ordered manner Protein phosphatase, enzyme that removes phosphate groups that have been attached to amino acid residues of proteins Protein purification, series of processes intended to isolate a single type of protein from a complex mixture Protein sequencing, protein method Protein splicing, intramolecular reaction of a particular protein in which an internal protein segment is removed from a precursor protein Protein structure, unique three-dimensional shape of amino acid chains Protein targeting, mechanism by which a cell transports proteins to the appropriate positions in the cell or outside of it Protein-protein docking, the determination of the molecular structure of complexes formed by two or more proteins Protein-protein interaction, the association of protein molecules and the study of these associations from the perspective of biochemistry RACK protein, receptor responsible for the binding of active forms of the protein kinase C family of enzymes Secretory protein, protein which is secreted by a cell
At this stage another galectin, galectin-3, interacts with TRIM16 to guide selective autophagy of damaged lysosomes. TRIM16 gathers ULK1 and principal components (Beclin 1 and ATG16L1) of other complexes (Beclin 1-VPS34-ATG14 and ATG16L1-ATG5-ATG12) initiating autophagy, many of them being under negative control of mTOR directly such as the ULK1-ATG13 complex, or indirectly, such as components of the class III PI3K (Beclin 1, ATG14 and VPS34) since they depend on activating phosphorylations by ULK1 when it is not inhibited by mTOR. These autophagy-driving components physically and functionally link up with each other integrating all processes necessary for autophagosomal formation: (i) the ULK1-ATG13-FIP200/RB1CC1 complex associates with the LC3B/GABARAP conjugation machinery through direct interactions between FIP200/RB1CC1 and ATG16L1, (ii) ULK1-ATG13-FIP200/RB1CC1 complex associates with the Beclin 1-VPS34-ATG14 via direct interactions between ATG13's HORMA domain and ATG14, (iii) ATG16L1 interacts with WIPI2, which binds to PI3P, the enzymatic product of the class III PI3K Beclin 1-VPS34-ATG14. Thus, mTOR inactivation, initiated through GALTOR upon lysosomal damage, plus a simultaneous activation via galectin-9 (which also recognizes lysosomal membrane breach) of AMPK that directly phosphorylates and activates key components (ULK1, Beclin 1) of the autophagy systems listed above and further inactivates mTORC1, allows for strong autophagy induction and autophagic removal of damaged lysosomes.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.